RxDoctor Payments Data

Olajide Balogun, MD

Internal Medicine · Lugoff, SCNPI 1215997820

Payments from drug & device makers

$509in general payments, 2019–2025

Across 34 payments — averaging $14.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$91
  • Novo Nordisk$83
  • Lilly USA, LLC$49
  • Sanofi-aventis U.S. LLC$43
  • Amgen$43
  • Dexcom, Inc.$42
  • plus $159 from 7 others

What the payments were for

  • Food & beverage$509100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$509 in reported general payments places this provider in the 55th percentile of 1,498 internal medicine providers in South Carolina.

See all internal medicine providers in South Carolina

Medicare billing

Part B allowed, 2024
$192,452
Medicare patients
232
Services billed
2,620

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide332$383,922
EliquisApixaban199$173,247
OzempicSemaglutide136$156,495
FarxigaDapagliflozin Propanediol198$155,370
LinzessLinaclotide131$92,796
JardianceEmpagliflozin92$92,612
Trelegy ElliptaFluticasone/Umeclidin/Vilanter92$79,582
RybelsusSemaglutide62$71,957
EntrestoSacubitril/Valsartan36$46,305
TrulicityDulaglutide42$46,291
Breztri AerosphereBudesonide/Glycopyr/Formoterol55$44,063
Xigduo XrDapaglifloz Propaned/Metformin33$32,508
XareltoRivaroxaban20$30,629
JanuviaSitagliptin Phosphate33$25,836
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog37$23,644

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$49$430,213374 claims
Novo NordiskOzempic, Rybelsus$83$228,452198 claims
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort$91$220,140315 claims
PfizerEliquis, Abrysvo$32$185,227245 claims
AbbVieLinzess$18$92,796131 claims
Boehringer IngelheimJardiance$15$92,61292 claims
Johnson & JohnsonXarelto$23$30,62920 claims
MerckJanuvia$25$25,83633 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 1,498 internal medicine providers in South Carolina.

Other internal medicine in Lugoff

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →